Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: John McCarthy who wrote (839)	10/15/1998 10:56:00 AM
From: StockDoc	Read Replies (2) \| Respond to of 887

Good to see you here. This is my bi-monthly visit to the ol favorite to see how they're doing. Sad reminder of the poor design, using MTX as control. Nobody knows for sure whether MTX prolongs or shortens the life of patients, on average, with carcinomatous meningitis. Now we'll see Depocyt for lymphomatous meningitis. At least they probably used a real control population (Cytosar?). That drug probably prolongs the life of some lymphoma patients (approved). Let's see whether they provided scientific evidence that Depocyt helps these patients. I expect the FDA to keep its standards, however. The former case was less than perfect, and the FDA recognized this with a non-approvable letter. If the number of evaluable cases is low, the identity or difference tests are not OK, the prospective criteria are not met, I have hard time top believe that the FDA would create a precedent of approving the drug.